697 related articles for article (PubMed ID: 19222905)
1. Comparison of WHO and US FDA biowaiver dissolution test conditions using bioequivalent doxycycline hyclate drug products.
Strauch S; Jantratid E; Dressman JB
J Pharm Pharmacol; 2009 Mar; 61(3):331-7. PubMed ID: 19222905
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of dissolution tests for fexofenadine hydrochloride capsules and coated tablets.
Breier AR; Paim CS; Steppe M; Schapoval EE
J Pharm Pharm Sci; 2005 Aug; 8(2):289-98. PubMed ID: 16124939
[TBL] [Abstract][Full Text] [Related]
3. Classification of torasemide based on the Biopharmaceutics Classification System and evaluation of the FDA biowaiver provision for generic products of CLASS I drugs.
Khan MZ; Rausl D; Radosević S; Filić D; Danilovski A; Dumić M; Knezević Z
J Pharm Pharmacol; 2006 Nov; 58(11):1475-82. PubMed ID: 17132210
[TBL] [Abstract][Full Text] [Related]
4. Biowaiver monographs for immediate release solid oral dosage forms: Doxycycline hyclate.
Jantratid E; Strauch S; Becker C; Dressman JB; Amidon GL; Junginger HE; Kopp S; Midha KK; Shah VP; Stavchansky S; Barends DM
J Pharm Sci; 2010 Apr; 99(4):1639-53. PubMed ID: 19798752
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
Jantratid E; Prakongpan S; Amidon GL; Dressman JB
Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
[TBL] [Abstract][Full Text] [Related]
6. Choice of rotation speed (rpm) for bio-relevant drug dissolution testing using a crescent-shaped spindle.
Qureshi SA
Eur J Pharm Sci; 2004 Nov; 23(3):271-5. PubMed ID: 15489128
[TBL] [Abstract][Full Text] [Related]
7. The impact of formulation and process changes on in vitro dissolution and the bioequivalence of piroxicam capsules.
Piscitelli DA; Bigora S; Propst C; Goskonda S; Schwartz P; Lesko LJ; Augsburger L; Young D
Pharm Dev Technol; 1998 Nov; 3(4):443-52. PubMed ID: 9834946
[TBL] [Abstract][Full Text] [Related]
8. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
[TBL] [Abstract][Full Text] [Related]
9. Justification of metformin hydrochloride biowaiver criteria based on bioequivalence study.
Homsek I; Parojcić J; Dacević M; Petrović L; Jovanović D
Arzneimittelforschung; 2010; 60(9):553-9. PubMed ID: 21117498
[TBL] [Abstract][Full Text] [Related]
10. Dissolution test as a surrogate for quality evaluation of rifampicin containing fixed dose combination formulations.
Agrawal S; Panchagnula R
Int J Pharm; 2004 Dec; 287(1-2):97-112. PubMed ID: 15541917
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of dissolution test for ritonavir soft gelatin capsules based on in vivo data.
Rossi RC; Dias CL; Donato EM; Martins LA; Bergold AM; Fröehlich PE
Int J Pharm; 2007 Jun; 338(1-2):119-24. PubMed ID: 17343999
[TBL] [Abstract][Full Text] [Related]
12. Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Nifedipine.
Gajendran J; Krämer J; Shah VP; Langguth P; Polli J; Mehta M; Groot DW; Cristofoletti R; Abrahamsson B; Dressman JB
J Pharm Sci; 2015 Oct; 104(10):3289-98. PubMed ID: 26149619
[TBL] [Abstract][Full Text] [Related]
13. Agitation Rate and Time for Complete Dissolution in BCS Biowaivers Based on Investigation of a BCS Biowaiver for Dexketoprofen Tablets.
Garcia-Arieta A; Gordon J; Gwaza L; Mangas-Sanjuan V; Álvarez C; Torrado JJ
Mol Pharm; 2015 Sep; 12(9):3194-201. PubMed ID: 26237401
[TBL] [Abstract][Full Text] [Related]
14. Development of a two-step tier-2 dissolution method for blinded overencapsulated erlotinib tablets using UV fiber optic detection.
Lu X; Xiao B; Lo L; Bolgar MS; Lloyd DK
J Pharm Biomed Anal; 2011 Aug; 56(1):23-9. PubMed ID: 21620602
[TBL] [Abstract][Full Text] [Related]
15. Regulatory Perspectives on Strength-Dependent Dissolution Profiles and Biowaiver Approaches for Immediate Release (IR) Oral Tablets in New Drug Applications.
Suarez-Sharp S; Delvadia PR; Dorantes A; Duan J; Externbrink A; Gao Z; Ghosh T; Miksinski SP; Seo P
AAPS J; 2016 May; 18(3):578-88. PubMed ID: 26928450
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of dissolution test for lopinavir, a poorly water-soluble drug, in soft gel capsules, based on in vivo data.
Donato EM; Martins LA; Fröehlich PE; Bergold AM
J Pharm Biomed Anal; 2008 Jul; 47(3):547-52. PubMed ID: 18403160
[TBL] [Abstract][Full Text] [Related]
17. Controlled release reservoir mini tablets approach for controlling the drug release of Galantamine Hydrobromide.
Khatavkar UN; Shimpi SL; Kumar KJ; Deo KD
Pharm Dev Technol; 2012; 17(4):437-42. PubMed ID: 22697431
[TBL] [Abstract][Full Text] [Related]
18. In vitro evaluation of dissolution behavior for a colon-specific drug delivery system (CODES) in multi-pH media using United States Pharmacopeia apparatus II and III.
Li J; Yang L; Ferguson SM; Hudson TJ; Watanabe S; Katsuma M; Fix JA
AAPS PharmSciTech; 2002; 3(4):E33. PubMed ID: 12916927
[TBL] [Abstract][Full Text] [Related]
19. Bio-relevant dissolution testing of hard capsules prepared from different shell materials using the dynamic open flow through test apparatus.
Garbacz G; Cadé D; Benameur H; Weitschies W
Eur J Pharm Sci; 2014 Jun; 57():264-72. PubMed ID: 24021609
[TBL] [Abstract][Full Text] [Related]
20. Investigating the Discriminatory Power of BCS-Biowaiver in Vitro Methodology to Detect Bioavailability Differences between Immediate Release Products Containing a Class I Drug.
Colón-Useche S; González-Álvarez I; Mangas-Sanjuan V; González-Álvarez M; Pastoriza P; Molina-Martínez I; Bermejo M; García-Arieta A
Mol Pharm; 2015 Sep; 12(9):3167-74. PubMed ID: 26287948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
